Experimental Antidepressants Offer Faster Relief

ByABC News
March 24, 2008, 1:11 AM

Mar. 23 -- WEDNESDAY, Sept. 5 (HealthDay News) -- A new class of antidepressants dramatically cut the time needed to take effect when they were tested on rats, a study found.

The study authors, from McGill University in Montreal, Canada, said they hope the finding will spur research into the family of drugs, raising the prospect of faster-acting antidepressants.

But, as always with studies involving animals, the findings must first be confirmed in humans.

"The only way we'll know is when a clinical trial is done" involving humans, said Gerald Frye, Joseph H. Shelton professor of neuropharmacology and neurotoxicology at the Texas A&M Health Science Center College of Medicine's department of neuroscience and experimental therapeutics. "It looks promising from an animal standpoint, and the animal systems they're using are pretty good, but this can only predict. There's no guarantee."

Frye was not involved with the study, which is published in the Sept. 6 issue of the journal Neuron.

Antidepressant drugs known as selective serotonin reuptake inhibitors (SSRIs), which include Prozac and Celexa, are widely prescribed but can take up to six weeks to take effect, and they don't work for everyone. Many patients have to try several different drugs before achieving success, and only about 65 percent of people end up responding to a drug, according to an accompanying editorial in the journal.

That time lag can be critical for someone suffering from depression. "During that time, there is a risk of suicide," Frye said. "Anything you can do to get a faster response" is desirable, he added.

SSRIs work by enhancing the action of the neurotransmitter serotonin in the brain.

The new study looked at a new class of drugs known as serotonin4 (5-HT4) receptor agonists, which have a more specific effect.

"SSRIs interfere with the serotonin system and increase naturally transmitted serotonin to help the system readjust itself," Frye explained. "The new drugs act only on one receptor. They're more selective."